Latest Breaking News On - Lung cancer biomarkers - Page 1 : vimarsana.com

Share this article Share this article ResearchAndMarkets.com s offering. The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand, the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market. The consumables segment accounted for the highest growth rate in the immuno-oncology assays market, by product & service, during the forecast period

United statesMerck milliporeAsia pacificTechnologietransfer gmbLaura woodSoftware servicesNanostring technologies incDynamic companiesMeso scale diagnosticsGuardant health incProgressive companiesSeegene incHtg molecular diagnostics incPorter five forces analysisRoche ltdInvivoscribe inc